Core Insights - The company Baixinan-B (02185) announced that its subsidiary, Shanghai Antong Medical Technology Co., Ltd. (Antong), has successfully registered the Iberis Renal Denervation (RDN) system with the UK's Medicines and Healthcare products Regulatory Agency (MHRA) [1] - Antong has formed a strategic partnership with Bosheng International Group Ltd. (Bosheng) for the commercialization of the Iberis RDN system across multiple regions, including the EU, Asia-Pacific, and Latin America [1] - The Iberis RDN system is currently the only RDN product globally approved for both transradial access (TRA) and transfemoral access (TFA), enhancing safety, efficacy, and cost-effectiveness of the procedure [1] Company Overview - Bosheng is a company registered in Bermuda and is a subsidiary of Shenzhen Stock Exchange-listed Blue Sail Medical Co., Ltd. (stock code: 002382), focusing on cardiovascular business [2] - Bosheng operates globally with its headquarters in Singapore and European headquarters in Morges, Switzerland, aiming to meet healthcare needs through a combination of direct sales and a global distribution network [2] - The company is committed to supporting medical education and advancing patient care by organizing training courses, scientific summits, and related activities at international and national levels [2]